CoChat
Sign Up
Cited by 125Cancer Immunotherapy and BiomarkersPharmacovigilance and Adverse Drug ReactionsImmunotherapy and Immune Responses

Harnessing big data to characterize immune-related adverse events

Jing, Ying, Yang, Jingwen, Johnson, Douglas B., Moslehi, Javid J., Han, Leng·2022·Nature Reviews Clinical Oncology
DOI 10.1038/s41571-021-00597-8
Open this paper in CoChat — free account

Abstract

Immune-checkpoint inhibitors (ICIs) have transformed patient care in oncology but are associated with a unique spectrum of organ-specific inflammatory toxicities known as immune-related adverse events (irAEs). Given the expanding use of ICIs, an increasing number of patients with cancer experience irAEs, including severe irAEs. Proper diagnosis and management of irAEs are important to optimize the quality of life and long-term outcomes of patients receiving ICIs; however, owing to the substantial heterogeneity within irAEs, and despite multicentre initiatives, performing clinical studies of these toxicities with a sufficient cohort size is challenging. Pioneering studies from the past few years have demonstrated that aggregate clinical data, real-world data (such as data on pharmacovigilance or from electronic health records) and multi-omics data are alternative tools well suited to investigating the underlying mechanisms and clinical presentations of irAEs. In this Perspective, we summarize the advantages and shortcomings of different sources of 'big data' for the study of irAEs and highlight progress made using such data to identify biomarkers of irAE risk, evaluate associations between irAEs and therapeutic efficacy, and characterize the effects of demographic and anthropometric factors on irAE risk. Harnessing big data will accelerate research on irAEs and provide key insights that will improve the clinical management of patients receiving ICIs.

Integrity signals

Registry

Crossref · 10.1038/s41571-021-00597-8

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • ICI targeting PD-1 and CTLA-4 is clinically effective in enhancing T-cell-mediated antitumor responses.

    “Although proving to be clinically effective in enhancing T-cell-mediated antitumor responses”

    From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [169]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Jing, Y., Yang, J., Johnson, D. B., Moslehi, J. J., & Han, L.
Affiliations
  • Shanghai Jiao Tong University (CN)
  • Texas A&M University (US)
  • Vanderbilt University Medical Center (US)
  • University of California, San Francisco (US)
Corresponding author
  • Johnson, Douglas B.
  • Moslehi, Javid J.
  • Han, Leng
ORCID
Venue
Nature Reviews Clinical Oncology
Publisher
Springer Science and Business Media LLC
Published
2022-01-17
Volume
19
Issue
4
Pages
269-280
ISSN
  • 1759-4774 (ISSN-L)
  • 1759-4782
DOI
10.1038/s41571-021-00597-8
OpenAlex
W4205294804
Cited by
125
References
32
Citations by year
2026: 14 · 2025: 35 · 2024: 37 · 2023: 31 · 2022: 8
FWCI
3.45
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Reviews Clinical Oncology (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Heart, Lung, and Blood Institute (R01HL141466, R01HL156021, R01HL155990)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
immune-related adverse events, immune checkpoint inhibitors, big data, real-world data, pharmacovigilance, electronic health records, multi-omics data, cancer immunotherapy toxicity
MeSH terms
Big Data, Immune Checkpoint Inhibitors, Humans, Neoplasms, Quality of Life

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review